Every Form 4 that Cardlytics (CDLX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CDLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDLX filings page.
Cardlytics, Inc. (symbol: CDLX) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cardlytics, Inc. (symbol: CDLX) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cardlytics, Inc. (symbol: CDLX) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cardlytics, Inc. (symbol: CDLX) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cardlytics, Inc. (symbol: CDLX) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cardlytics, Inc. (symbol: CDLX) is the issuer of record for a Form 4/A filing submitted to the SEC.
Cardlytics, Inc. (CDLX) reported insider equity activity by Chief Executive Officer Amit Gupta. On August 16, 2026, Gupta acquired 25,000 shares of common stock upon the vesting and conversion of 25,000 Restricted Stock Units (RSUs), each RSU representing a contingent right to receive one share of common stock. These RSUs relate to two separate 50,000-share RSU awards granted on August 21, 2024 and January 29, 2025, which vest in four equal 25% installments over 24 months following August 16, 2024, subject to continued employment. On August 17–18, 2026, Gupta sold an aggregate of 13,461 shares of common stock in open-market or private transactions at weighted average prices of $3.966 and $4.031 per share, respectively. The filing’s Rule 10b5-1 checkbox indicates these sales were not made pursuant to a Rule 10b5-1 trading plan.
Cheng Christopher Chi-Kit reported acquisition or exercise transactions in this Form 4 filing.
Cardlytics, Inc. granted 50,000 Restricted Stock Units (RSUs) to Chief Legal & Privacy Officer Christopher Chi-Kit Cheng. Each RSU represents a contingent right to receive one share of Common Stock. The award vests over 24 months, with 25,000 units vesting on September 1, 2027 and the remainder vesting quarterly over the following 12 months, subject to continued employment. Following this grant, Cheng holds 50,000 RSUs directly.
Cardlytics, Inc. director and CEO Amit Gupta reported a mix of RSU conversions and open-market sales of Common Stock. On July 1, 2026, he converted 18,750 and 12,500 Restricted Stock Units into the same number of Common Stock shares at a conversion price of $0.00 per share. On July 2, 2026 and July 6, 2026, he then sold 6,498 and 9,640 Common Stock shares, respectively, at weighted average prices of about $4.40 per share. Following these transactions, Gupta directly holds 113,850 Common Stock shares. The filing notes a 1-for-10 reverse stock split effective June 5, 2026, and explains that RSU awards continue to vest in scheduled quarterly installments through April 1, 2027 and April 1, 2028, subject to ongoing employment.
Cardlytics, Inc.’s Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer reported a combination of RSU vesting and a related share sale. On July 1, 2026, he exercised restricted stock units that delivered a total of 4,719 shares of Common Stock. On July 2, 2026, he sold 2,151 shares of Common Stock at a weighted average price of $4.395 per share, with footnotes stating the sale was made solely to cover tax withholding obligations from the RSU share delivery. Following these transactions, he directly holds 19,353 shares of Cardlytics common stock, with no remaining derivative positions shown in this filing.
Cardlytics, Inc. director Srishti A. Gupta reported routine equity compensation activity. On May 20, 2026, Gupta exercised 11,000 restricted stock units, receiving the same number of common shares at a price of $0.00 per share. This increased her directly held common stock to 17,148 shares after the transaction.
On the same date, Gupta received a new grant of 11,000 restricted stock units, each representing a contingent right to one share of Cardlytics common stock or its cash equivalent. According to the terms, these new RSUs vest in full on the one-year anniversary of the grant if she remains a director on that date.
Cardlytics director Francis Jonathan Edward reported routine equity compensation changes. On May 20, 2026, he exercised 11,000 restricted stock units into the same number of common shares and received a new grant of 11,000 RSUs. He now directly holds 26,310 common shares and 11,000 RSUs, which will vest one year after grant if he remains a director.
Cardlytics director Scott A. Hill increased his equity exposure through compensation-related transactions. He exercised 11,000 restricted stock units into 11,000 shares of common stock, and separately received a new grant of 11,000 RSUs that will vest in full after one year of continued board service. Following these moves, he holds 68,748 shares of common stock directly and 11,000 RSUs representing a contingent right to additional shares or their cash equivalent.
Cardlytics, Inc. director Andre J. Fernandez increased his equity-based holdings through routine compensation activity. He exercised 11,000 restricted stock units into 11,000 shares of common stock after they vested in full on the one-year anniversary of their grant. Following this exercise, he directly owns 26,310 shares of common stock.
On the same date, he received a new grant of 11,000 restricted stock units, each representing a right to receive one share of Cardlytics common stock or its cash equivalent at the company’s election. These new RSUs will vest in full on the one-year anniversary of the grant, assuming he continues to serve as a director.
Cardlytics director Liane Hornsey reported routine equity compensation activity. She acquired 11,000 shares of Common Stock through the vesting and conversion of previously granted restricted stock units (RSUs), leaving her with 33,326 Common shares held directly after the transactions.
On the same date, she also received a new grant of 11,000 RSUs, each representing a contingent right to one Cardlytics common share or its cash equivalent, which will vest in full on the one-year anniversary of the grant if she remains a director.
Cardlytics director John L. Klinck Jr. reported equity compensation activity involving the company’s common stock. He acquired 11,000 shares of common stock through the vesting and exercise of previously granted restricted stock units that converted into an equal number of shares.
On the same date, he received a new award of 11,000 restricted stock units, each representing a contingent right to one share of common stock or its cash equivalent. After these transactions, he directly holds 89,593 shares of common stock and 11,000 restricted stock units that are scheduled to vest in full on the one-year anniversary of the grant date, so long as he continues serving as a director.
Cardlytics, Inc. Chief Financial Officer David Thomas Evans reported open-market purchases of a total of 200,000 shares of common stock. He bought 150,000 shares on May 15, 2026 at a weighted average price of $0.649 per share and 50,000 shares on May 18, 2026 at a weighted average price of $0.633 per share.
Both trades were direct, non-derivative purchases. After these transactions, Evans directly owned 317,930 shares of Cardlytics common stock. Footnotes explain that each reported price is a weighted average across multiple individual trades executed within narrow price ranges on the respective dates.
Cardlytics, Inc. director and Chief Executive Officer Amit Gupta reported an open-market sale of 69,833 shares of common stock at a weighted average price of $1.187 per share. According to the filing, the shares were sold solely to satisfy tax withholding obligations from RSUs that vested on April 1, 2026, and were not sold for any other purpose. Following this tax-related sale, Gupta continues to hold 987,387 shares of Cardlytics common stock directly.
Cardlytics, Inc. Chief Executive Officer Amit Gupta reported RSU vesting and related share sales. On April 1, 2026, he acquired 514,350 shares of common stock at a conversion price of $0.00 per share through the exercise of restricted stock units. The same day and on April 2, 2026, he sold a total of 116,774 common shares at weighted average prices of $0.99 and $1.042 per share. Footnotes state these sales were made solely to satisfy tax withholding obligations from RSUs that vested on April 1, 2026 and were not for any other purpose. After these transactions, he directly held 1,057,220 shares of Cardlytics common stock.
Cardlytics, Inc. Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer exercised restricted stock units into 85,290 shares of common stock on April 1, 2026. He then sold 40,296 shares at a weighted average price of $0.99 solely to cover tax withholding obligations, and now directly holds 167,856 shares.
Gupta Amit reported acquisition or exercise transactions in this Form 4 filing.
Cardlytics, Inc. Chief Executive Officer Amit Gupta received an equity grant of 1,500,000 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Cardlytics common stock at no purchase price.
The RSU award will vest in equal amounts quarterly over a two-year period through April 1, 2028, as long as Gupta remains employed by Cardlytics on each vesting date. This award increases his directly held RSUs to 1,500,000, further tying his compensation to the company’s future share performance.
Cardlytics, Inc. reported that Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer acquired 220,000 restricted stock units (RSUs) as an equity award. Each RSU represents a right to receive one share of common stock. The award vests in equal quarterly installments over two years through April 1, 2028, contingent on his continued employment with the company.
Cardlytics, Inc. Chief Executive Officer Amit Gupta reported a combination of stock vesting and related share sales. On February 16, 2026, he acquired 250,000 shares of common stock through the exercise/settlement of restricted stock units (RSUs), each RSU representing the right to receive one share or its cash equivalent.
According to the filing, Gupta then sold a total of 97,208 common shares on February 17–18, 2026 in open-market transactions at weighted average prices of $0.902 and $0.926 per share. A footnote states these sales were made solely to satisfy tax withholding obligations arising from the RSU share delivery and not for any other purpose. After these transactions, Gupta directly owned 659,644 common shares.
The RSU awards referenced cover 500,000 shares each, granted on August 21, 2024 and January 29, 2025, and vest in four 25% installments over 24 months following August 16, 2024, conditioned on continued employment.
Cardlytics, Inc. Chief Financial Officer Evans David Thomas received an award of 1,000,000 restricted stock units (RSUs) on January 12, 2026. Each RSU represents a contingent right to receive one share of Cardlytics common stock. The filing shows these derivative securities are held directly and that the total RSUs beneficially owned after the transaction is 1,000,000.
The vesting schedule is time-based. Half of the RSUs, or 50% of the underlying shares, will vest on February 1, 2027. The remaining 50% will then vest in equal quarterly installments over the following year through February 1, 2028, as long as the executive remains employed by Cardlytics on each vesting date. This structure is designed to align the CFO’s compensation with the company’s long-term performance and retention.
Cardlytics (CDLX) reported an insider equity change by a director. On October 30, 2025, 6,148 restricted stock units converted into 6,148 shares of common stock, shown with transaction code M (conversion of a derivative security) at a stated price of $0, consistent with RSU settlement.
The RSUs were granted on October 30, 2024 and vested in full one year later. After the settlement, the reporting person holds 6,148 shares with direct ownership. No sales were reported in this filing.
Nick Lynton, Chief Legal & Privacy Officer of Cardlytics, Inc. (CDLX), reported multiple vesting and a sale related to restricted stock units. On 10/01/2025 the reporting person had 10,630, 581 and 1,578 RSUs treated as acquired (each converts into one share) and those awards increased their reported beneficial ownership to 122,425 shares before a sale. On 10/02/2025 the reporting person sold 6,098 shares at a weighted average price of $2.271 (individual sale prices ranged $2.21–$2.36) and the filing shows 116,327 shares owned after the sale. The filing states the sale was made solely to satisfy tax withholding from RSU vesting and discloses original grant sizes and vesting schedules for each RSU award.
Amit Gupta, Cardlytics, Inc. (CDLX) Chief Executive Officer and director, reported vesting and sales tied to restricted stock units. On 10/01/2025 14,350 RSUs vested (each convertible into one share) and were recorded as an acquisition event. To cover tax withholding for that vesting, 7,799 shares were sold on 10/02/2025 at a weighted average price of $2.271, with reported sale prices ranging from $2.21 to $2.36. After these transactions, the Reporting Person beneficially owned 498,310 shares directly and had 28,699 RSU-based shares remaining that will convert to common stock if vesting conditions are met. The original RSU grant totaled 114,796 shares and vests in eight equal installments through 04/01/2026.